Amgen (Nasdaq: AMGN) announced the results of a national Harris Interactive, Inc. survey indicating that the vast majority of oncologists and infectious disease (ID) specialists are highly concerned about the negative impact infection may have on treatment outcomes in chemotherapy patients, as well as emerging antibiotic resistance. Nearly all oncologists surveyed (92 percent) believe it is important for cancer patients to prevent infections to achieve successful treatment outcomes. bayer pharmaceutical
Schering-Plough Corporation (NYSE: SGP) reported that final results of three large PEGINTRON(TM) (peginterferon alfa-2b) clinical studies address longstanding questions in the hepatitis C research community and provide important insights. The results of the studies, involving a total of more than 2,700 patients, were presented at the 44th European Association for the Study of the Liver (EASL) 2009 Annual Meeting. bayer pharmaceutical
DUBLIN—-Research and Markets has announced the addition of the “The Pharmaceutical Market: Colombia” report to their offering.Research and Markets: The Pharmaceutical Market: Colombia – Colombia’s GDP Is Expected To Shrink From US$240.8 Billion . (Business Wire Finance)
Phase 3 Trial Initiated To Evaluate Combination Therapy Of Nexavar(R) And Tarceva(R) In Patients With Liver Cancer (Medical News Today)Bayer HealthCare LLC., Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX), OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) and Roche today announced the initiation of a Phase 3 trial examining Nexavar(R) (sorafenib) tablets in combination with Tarceva(R) (erlotinib) tablets as a potential new treatment option for patients with advanced hepatocellular carcinoma (HCC), or primary liver cancer.
“Nexavar is the only approved targeted therapy with efficacy and tolerability in liver cancer,” said Dimitris Voliotis, MD, vice president, Nexavar Clinical Development, Bayer HealthCare Pharmaceuticals. “We look forward to seeing the .World Pharma News – Phase III Trial Started to Evaluate .
The Amex Pharmaceutical Index was largely flat at 253.11 and the Amex Biotechnology Index slipped 0.6% to 628.62. The Dow Jones Industrial Average was off only about 15 points at 8388. Bayer shares were up 4% at $56.80. .Drug stocks mixed; Bayer climbs after FDA decision – MarketWatch
